This is a summary of the American Academy of Neurology and Society for Neuro-Oncology’s neuro-oncology quality measurement set. Please refer to the full measurement set at AAN.com/policy-and-guidelines/quality/quality-measures2/quality-measures/other/ for more information, including the complete set of measurement specifications. These measures use the following formulas to identify quality of care performance.

\[
\text{QUALITY OF PATIENT CARE} = \frac{\text{Patients Who Meet Criterion}}{(\text{Eligible Population} - \text{Exclusions})}
\]

### Multidisciplinary Care Plan Developed for Primary Brain or Spine Tumors

**MEASURE PURPOSE:** Ensure multidisciplinary care.

**TO MEET THE MEASURE:** Develop a multidisciplinary tumor board treatment plan for patients with a new diagnosis of primary brain or spine Central Nervous System (CNS) World Health Organization (WHO) grade II-IV tumor.

**NUMERATOR:** Patients with a multidisciplinary tumor board treatment plan* developed in the 12-month measurement period.

**DENOMINATOR:** All patients diagnosed in the measurement period with a new diagnosis of primary brain or spine CNS WHO grade II-IV tumor.

<table>
<thead>
<tr>
<th>EXCLUSION: None</th>
</tr>
</thead>
</table>

**Quality of care provided to your patients with a new diagnosis of grade II-IV primary brain or spine tumor**

### Molecular Testing in Accordance with World Health Organization Classification of Tumors of the Central Nervous System

**MEASURE PURPOSE:** Increase rates of molecular testing.

**TO MEET THE MEASURE:** Perform molecular testing in accordance with most recent WHO classification for patient’s initial resection or biopsy of grade II-IV glioma.

**NUMERATOR:** Patients with molecular testing* performed in accordance with most recent WHO classification flow.

**DENOMINATOR:** Patients 18 years and older who have had an initial resection or biopsy of grade II-IV glioma.

<table>
<thead>
<tr>
<th>EXCLUSION: Patients with insufficient tissue sample for molecular testing</th>
</tr>
</thead>
</table>

**Quality of care provided to your patients with grade II-IV glioma who had an initial resection or biopsy**

### Chemotherapy Education and Informed Consent for Brain Tumor Patients

**MEASURE PURPOSE:** Increase chemotherapy education and informed consent rates.

**TO MEET THE MEASURE:** Prior to prescribing chemotherapy provide education and obtain an informed consent for patients with a brain tumor.

**NUMERATOR:** Patients who were provided chemotherapy education* AND for whom informed consent was obtained prior to prescription of chemotherapy.

**DENOMINATOR:** Patients 18 years and older with a diagnosis of brain tumor who were prescribed chemotherapy outside of a clinical trial.

<table>
<thead>
<tr>
<th>EXCLUSION: Patients that received education and active consent obtained for same chemotherapy prescription in the past 12-month period</th>
</tr>
</thead>
</table>

**Quality of care provided to your patients with a brain tumor prescribed chemotherapy outside of a clinical trial**

---

*See full specifications for additional details at AAN.com/policy-and-guidelines/quality/quality-measures2/quality-measures/other/
Intra-operative or post-operative MRI for gliomas

**MEASURE PURPOSE:** Ensure MRI completed in a timely manner.

**TO MEET THE MEASURE:**
Obtain a post-operative or intra-operative MRI for patients with a grade III-IV glioma who had a surgical resection.

**NUMERATOR:** Patients who had a post-operative* gadolinium enhanced MRI of the brain or an intraoperative* MRI of the brain with or without gadolinium.

**DENOMINATOR:** Patients 18 years and older with a diagnosis of grade III-IV glioma who undergo a surgical resection.

**EXCLUSIONS:**
- Patients with a contraindication for MRI (i.e., presence of pacemaker, intracranial metal clip, metallic body in the eye, or neurostimulator).
- Patients with a contraindication for receiving gadolinium.
- Patients who undergo surgery for purposes other than cytoreduction (i.e., diagnostic biopsy only).

Venous Thromboembolism Events (VTE) Following Primary Brain Tumor Surgery

**MEASURE PURPOSE:** Reduce the number of VTE following primary brain tumor surgery.

**TO MEET THE MEASURE:** Count the number of VTE following primary brain tumor surgery.

**NUMERATOR:** Patients who experience a deep vein thrombosis (DVT) or pulmonary embolism (PE) event during their immediate post-surgical hospitalization, identified on diagnostic testing performed.

**DENOMINATOR:** All patients who had resection or biopsy of grade III-IV glioma

**EXCLUSION:**
- DVT or PE present at admission

*See full specifications for additional details at AAN.com/practice/quality-measures.